178 related articles for article (PubMed ID: 3204664)
21. [Effect of immunotherapy using the non-specific immunopotentiator OK-432 in malignant ovarian tumors--selecting appropriate cases for immunotherapy].
Nishida Y; Sakakibara K; Kano T; Ohta M; Tomoda Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jul; 38(7):1017-25. PubMed ID: 3746020
[TBL] [Abstract][Full Text] [Related]
22. [Adjuvant immunochemotherapy with long-term OK-432 administration in colorectal cancer].
Kikkawa N; Sasai H; Kawahara T
Gan To Kagaku Ryoho; 1984 Oct; 11(10):2163-9. PubMed ID: 6486832
[TBL] [Abstract][Full Text] [Related]
23. [Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer].
Yamane T; Sagara Y; Suzuki G; Kasuga M; Sakita M; Fujita Y; Majima S
Gan To Kagaku Ryoho; 1984 Apr; 11(4):930-4. PubMed ID: 6721507
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer.
Oba K; Teramukai S; Kobayashi M; Matsui T; Kodera Y; Sakamoto J
Cancer Immunol Immunother; 2007 Jun; 56(6):905-11. PubMed ID: 17106715
[TBL] [Abstract][Full Text] [Related]
25. [Influence of OK 432 upon postoperative alteration in activities producing lymphokines, IL 1, IL 2, and IFN, of peripheral blood mononuclear cells derived from patients with gastric cancer].
Hosoi J
Nihon Gan Chiryo Gakkai Shi; 1987 Apr; 22(3):603-13. PubMed ID: 2443588
[No Abstract] [Full Text] [Related]
26. [Observation on natural killer cell activity in gastric cancer patients and effect of nonspecific immunopotentiator administration on its postoperative reduction].
Oshita H; Saji S; Sugiyama Y; Tanemura H; Sakata K; Tanaka S; Ito T
Nihon Geka Gakkai Zasshi; 1985 Oct; 86(10):1417-25. PubMed ID: 4079897
[TBL] [Abstract][Full Text] [Related]
27. Hemolytic streptococcus preparation OK-432; beneficial adjuvant therapy in recurrent gastric carcinoma.
Hanaue H; Kim DY; Machimura T; Tsukui M; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H
Tokai J Exp Clin Med; 1987 Nov; 12(4):209-14. PubMed ID: 3503390
[TBL] [Abstract][Full Text] [Related]
28. [Clinical trial of oral immunotherapy with streptococcal preparation OK 432 on gastric cancer].
Nio Y; Ohgaki K; Henmi K; Kan N; Inamoto T; Tsuchitani T; Kodama H; Tobe T
Nihon Gan Chiryo Gakkai Shi; 1982 Apr; 17(3):728-34. PubMed ID: 6752308
[No Abstract] [Full Text] [Related]
29. Immunotherapy of patients with terminal-stage malignant tumors with an immunopotentiator OK-432--a comparison of SU-PS test-responding and -nonresponding patients.
Yagi Y; Yagi S
Int J Immunopharmacol; 1988; 10(4):451-61. PubMed ID: 3049405
[TBL] [Abstract][Full Text] [Related]
30. [Immunotherapy of gastric cancer].
Kan N; Ohgaki K; Okino T; Nakanishi M; Nio Y; Inoue K; Tobe T
Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 2-1):755-62. PubMed ID: 3291771
[TBL] [Abstract][Full Text] [Related]
31. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
[TBL] [Abstract][Full Text] [Related]
32. [Immunotherapy for lung cancer by streptococcal preparation OK-432].
Watanabe Y; Shimizu J; Yoshida Y; Hashizume Y; Yamada T; Iwa T
Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1432-5. PubMed ID: 2586434
[TBL] [Abstract][Full Text] [Related]
33. [Administration of hemolytic streptococcus preparation OK-432 on recurrent gastric carcinoma].
Hanaue H; Kurosawa T; Kitano Y; Miyagawa S; Nemoto A; Yamato H; Asagoe T; Shikata J
Nihon Gan Chiryo Gakkai Shi; 1987 Aug; 22(7):1367-72. PubMed ID: 3501455
[No Abstract] [Full Text] [Related]
34. Intraperitoneal administration of the biological response modifier OK-432 and peritoneal recurrence following gastrectomy.
Tsujitani S; Abe Y; Korenaga D; Saitoh A; Watanabe A; Sugimachi K
Hepatogastroenterology; 1990 Oct; 37(5):498-502. PubMed ID: 2253926
[TBL] [Abstract][Full Text] [Related]
35. [The clinical value of long-term administration of OK-432 in head and neck cancer].
Mitarai K; Tsukuda M; Tamamushi N; Mochimastu I; Kubota A; Sawaki S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):945-50. PubMed ID: 3963858
[TBL] [Abstract][Full Text] [Related]
36. [Effect of intraperitoneal therapy in gastric cancer with peritoneal dissemination].
Kajiura Y; Ogoshi K; Nakamura K; Miyaji M; Kondoh Y; Makuuchi H; Tajima T; Mitomi T
Gan To Kagaku Ryoho; 1997 Sep; 24(12):1863-6. PubMed ID: 9382552
[TBL] [Abstract][Full Text] [Related]
37. [Effect of endoscopical administration of OK-432 in 4 patients with advanced esophageal or gastric cancer].
Satomi T; Inoue S; Fujita T; Ogawa S; Honda H; Hayashi M
Gan No Rinsho; 1989 Mar; 35(4):512-5. PubMed ID: 2541269
[TBL] [Abstract][Full Text] [Related]
38. [Suppressor function of the blood lymphocytes in patients with stomach cancer undergoing gastrectomy combined with splenectomy].
Kadagidze ZG; Zhogoleva IB; Popova SR; Ibragimov SS
Eksp Onkol; 1988; 10(4):46-9. PubMed ID: 2846261
[TBL] [Abstract][Full Text] [Related]
39. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer.
Watanabe Y; Iwa T
J Biol Response Mod; 1987 Apr; 6(2):169-80. PubMed ID: 3585412
[TBL] [Abstract][Full Text] [Related]
40. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
